Free Trial

Revvity (RVTY) Stock Forecast & Price Target

$113.38
+0.26 (+0.23%)
(As of 07/17/2024 ET)

Revvity - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 16 Wall Street analysts who have issued ratings for Revvity in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 7 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for RVTY.

Consensus Price Target

$119.14
5.08% Upside
High Forecast$133.00
Average Forecast$119.14
Low Forecast$95.00

According to the 16 analysts' twelve-month price targets for Revvity, the average price target is $119.14. The highest price target for RVTY is $133.00, while the lowest price target for RVTY is $95.00. The average price target represents a forecasted upside of 5.08% from the current price of $113.38.

TypeCurrent Forecast
7/18/23 to 7/17/24
1 Month Ago
6/18/23 to 6/17/24
3 Months Ago
4/19/23 to 4/18/24
1 Year Ago
7/18/22 to 7/18/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
2 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
6 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$119.14$117.92$118.91$145.00
Forecasted Upside5.08% Upside12.88% Upside12.31% Upside18.50% Upside
Get Revvity Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RVTY and its competitors with MarketBeat's FREE daily newsletter.

RVTY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RVTY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Revvity Stock vs. The Competition

TypeRevvityMedical CompaniesS&P 500
Consensus Rating Score
2.63
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside4.60% Upside1,211.76% Upside7.68% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/8/2024Leerink Partnrs
0 of 5 stars
P. Souda
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/8/2024SVB Leerink
1 of 5 stars
 Initiated CoverageOutperform$125.00+20.70%
6/28/2024Barclays
2 of 5 stars
 Lower TargetEqual Weight ➝ Equal Weight$116.00 ➝ $115.00+9.77%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$115.00+5.83%
4/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$126.00 ➝ $127.00+22.61%
4/30/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$123.00 ➝ $130.00+25.18%
2/2/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$95.00 ➝ $110.00+4.35%
2/2/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$106.00 ➝ $127.00+18.68%
2/2/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$110.00 ➝ $126.00+17.75%
1/16/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$105.00 ➝ $125.00+12.82%
1/4/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeIn-Line ➝ Outperform$88.00 ➝ $125.00+19.02%
12/19/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageEqual Weight$95.00-6.23%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoveragePeer Perform
10/31/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$120.00 ➝ $105.00+27.07%
10/17/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$130.00 ➝ $110.00+4.17%
9/28/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$133.00+21.96%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:32 PM ET.

RVTY Forecast - Frequently Asked Questions

What is Revvity's forecast for 2024?

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Revvity is $119.14, with a high forecast of $133.00 and a low forecast of $95.00.

Should I buy or sell Revvity stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revvity in the last twelve months. There are currently 7 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RVTY shares.

Does Revvity's stock price have much upside?

According to analysts, Revvity's stock has a predicted upside of 14.38% based on their 12-month stock forecasts.

Has Revvity been upgraded by Wall Street analysts recently?

Over the previous 90 days, Revvity's stock had 1 upgrade by analysts.

What analysts cover Revvity?

Revvity has been rated by research analysts at Barclays, Jefferies Financial Group, Leerink Partnrs, Robert W. Baird, SVB Leerink, and TD Cowen in the past 90 days.

Do Wall Street analysts like Revvity more than its competitors?

Analysts like Revvity less than other "medical" companies. The consensus rating score for Revvity is 2.63 while the average consensus rating score for "medical" companies is 2.71. Learn more on how RVTY compares to other companies.


This page (NYSE:RVTY) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners